(a)
(b)
(c)
(d)
Figure 3: The dual-luciferase reporter assay indicates that ADAM10 is the direct target of miR-103a/107. (a) Luciferase activities on the cotransfection of the reporter plasmid with normal ADAM10 3′UTR (blank, ; hsa-mir-103a-3p, ; hsa-mir-103a-3p inhibitor, ; NC, ; NC inhibitor, ; p, 3′UTR ADAM10 + hsa-mir-103a-3p/3′UTR ADAM10, 0.000155; 3′UTR ADAM10 + hsa-mir-103a-3p/3′UTR ADAM10 + NC, 0.004107; 3′UTR ADAM10 + hsa-mir-103a-3p inhibitor/3′UTR ADAM10, 0.002351; 3′UTR ADAM10 + hsa-mir-103a-3p inhibitor/3′UTR ADAM10 + NC inhibitor, 0.011695); (b) the effect of mutated ADAM10 3′UTR on the luciferase activity when cotransfecting blank, human miR-103a-3p, 103a inhibitor, NC, or NC inhibitor (blank, ; hsa-mir-103a-3p, ; hsa-mir-103a-3p inhibitor, ; NC, ; NC inhibitor, ; p, 3′UTR mut ADAM10 + hsa-mir-103a-3p/3′UTR mut ADAM10, 0.933656; 3′UTR mut ADAM10 + hsa-mir-103a-3p/3′UTR mut ADAM10 + NC, 0.346206; 3′UTR mut ADAM10 + hsa-mir-103a-3p inhibitor/3′UTR mut ADAM10, 0.177698; 3′UTR mut ADAM10 + hsa-mir-103a-3p inhibitor/3′UTR mut ADAM10 + NC inhibitor, 0.811131); (c) luciferase activities on the cotransfection of the reporter plasmid with normal ADAM10 3′UTR (blank, ; hsa-mir-107, ; hsa-mir-107 inhibitor, ; NC, ; NC inhibitor, ; p, 3′UTR ADAM10 + hsa-mir-107/3′UTR ADAM10, 0.001753; 3′UTR ADAM10 + hsa-mir-107/3′UTR ADAM10 + NC, 0.000443; 3′UTR ADAM10 + hsa-mir-107 inhibitor/3′UTR ADAM10, 0.020667; 3′UTR ADAM10 + hsa-mir-107 inhibitor/3′UTR ADAM10 + NC inhibitor, 0.013883); (d) the effect of mutated ADAM10 3′UTR on the luciferase activity when cotransfecting blank, human miR-107, 107 inhibitor, NC, or NC inhibitor (blank, ; hsa-mir-107, ; hsa-mir-107 inhibitor, ; NC, ; NC inhibitor, ; p, 3′UTR mut ADAM10 + hsa-mir-107/3′UTR mut ADAM10, 0.020979; 3′UTR mut ADAM10 + hsa-mir-107/3′UTR mut ADAM10 + NC, 0.544506; 3′UTR mut ADAM10 + hsa-mir-107 inhibitor/3′UTR mut ADAM10, 0.516319; 3′UTR mut ADAM10 + hsa-mir-107 inhibitor/3′UTR mut ADAM10 + NC inhibitor, 0.677649). ; .